ClinicalTrials.gg
TerminatedNCT00518284Updated Mar 13, 2012Results posted

Prevention of Restenosis Following Revascularization

A Phase 2 interventional study of Nanoparticle Paclitaxel in Vascular Disease, Peripheral, sponsored by Celgene Corporation. Terminated at 7 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-03-13.

Sponsored by Celgene Corporation (part of Bristol-Myers Squibb) · Phase 2, Interventional, and Prevention

Why this study was terminated
Study was terminated due to changing sponsor priorities, and was not based on safety or outcomes data.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
6
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 187 studies in Peripheral Vascular Diseases with a site in United States — 18 open to participants now, 23 under way, 2 of them phase 3. Peripheral Vascular Diseases · United States.

Enrollment
152nd of 158
6 · median 82
Started
2008
with 12 others
Phase 2
24 of 187
1 open now
Registered
49th of 187
by date

Among the 187 studies in Peripheral Vascular Diseases with a site in United States, this one is the 152nd largest by enrollment of the 158 interventional ones that give a count, is one of 13 that started in 2008, is one of 24 in phase 2, and was the 49th registered.

Peripheral Vascular Diseases

443 studies on the registry are indexed under Peripheral Vascular Diseases; 44 are open to participants now.

Browse Peripheral Vascular Diseases studies →

Open to participants now

18 of the 187 studies in Peripheral Vascular Diseases with a site in United States are open now. Recruiting first, the newest first:

13 more — sign in →

All 18 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 32 Peripheral Vascular Diseases studies recruiting now, 19 (59%) set no upper age limit and 4 (13%) stop at 75 or younger; 2 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 187 studies in Peripheral Vascular Diseases with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to investigate the prevention of Restenosis following Revascularization of the superficial Femoral Artery (SFA)

03

Conditions studied

  • Vascular Disease, Peripheral

Keywords

  • Restenosis
  • Superficial Femoral Artery
  • Prevention of restenosis
  • Revascularization of the superficial Femoral Artery
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or non-pregnant and non-lactating female and greater than or equal to 18 years of age. All females if child bearing potential must have a negative serum pregnancy test
  • Patient is determined to have peripheral artery disease (PAD) classified as Rutherford category 1-4 (grade I/II) - mild, moderate, or severe claudication or ischemic rest pain
  • Patient has de novo lesion causing occlusion or an angiographic stenosis of at least 50% in the superficial femoral artery
  • Patient has a single or multiple lesions located in the superficial femoral artery with a total length 5-15 cm.
  • Normal vessel diameter of the SFA is 4-6 mm
  • Patient must have a visibly patent (by angiography) popliteal artery below the target lesion
  • No residual flow limiting dissection or residual stenosis greater 30% (visual estimate) after percutaneous balloon angioplasty (PTA) or provisional stenting. Treatment with provisional stenting will be allowed only for flow-limiting dissection, grade C/D or greater than 30 % residual stenosis angiographically after angioplasty alone.
  • No target vessel thrombosis confirmed angiography post-PTA procedure
  • No distal embolization within target limb
  • Patient or his/her legally authorized representative or guardian has been informed about the nature of the study, and has agreed to participate in the study, and signed the Form prior to any premedication, prior to performance of revascularization procedures, and prior to participation in any study-related activities

Exclusion criteria

Exclusion Criteria:

  • Women of child bearing potential who do not use adequate
  • Patients who have experienced acute onset of claudication
  • History of bleeding diathesis, coagulopathy, disorder, or thrombocytopenia
  • Patients with lesions requiring treatment with atherectomy or primary stenting
  • Target lesion in which PTA failure would require treatment by provisional stenting with more than 2 stents
  • Patient has a of less than 36 months or there are factors making clinical follow up difficult (no fixed address, etc)
  • Additional planned vascular procedure in treated extremity (note that concurrent endovascular treatment of iliac disease is allowable)
  • Patient is or is positive
  • Any individual who may refuse a blood transfusion
  • Documented major gastrointestinal bleeding within 3 months
  • The following lab values at baseline are exclusionary:
  • Serum creatinine greater or equal to 2.5 mg/dl
  • Platelet count less than 100,000 cells/mm\^3
  • Uncorrectable coagulopathy with (INR) greater than 2.0
  • (ANC) less than 2000 cells mm\^3
  • (Hgb) less than 9 g/dl
  • Total greater than 1.5 mg/dl
  • (SGPT) greater than 2.5 x upper limit normal range ()
  • Aspartate transaminase (SGOT) greater than 2.5 x ULN
  • Alkaline phosphatase greater than 2.5 x ULN
  • Total cholesterol greater than 350 mg/dl or Low Density Lipoprotein greater than 200 mg/dl
  • Known allergies// to the study drug, to taxanes, to any required study treatment:aspirin, heparin, clopidogrel bisulfate, stent materials, or to ticlopidine, or dipyridamole
  • Patient treated with bivalirudin (Angiomax)
  • Pre-existing sensory neuropathy of National Cancer Institute (NCI) Toxicity Grade >1
  • Previous participation in another study with any drug or device within the past 30 days or current enrollment in any other clinical protocol or investigational trial
  • Renal failure requiring hemodialysis
  • Lower extremity or pedal pulse
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
6 participants (actual)

Study arms

  • No intervention
    No Drug Treatment Control

    Following revascularization, participants did not receive any study drug treatment.

  • Experimental
    Proximal to Lesion + IV

    Participants received an initial intraarterial infusion (proximal to the lesion) of 45 mg/m\^2 nanoparticle paclitaxel immediately following revascularization, and a follow-up intravenous injection of 45 mg/m\^2 at 7 days.

    Drug: Nanoparticle Paclitaxel

  • Experimental
    During Flow Arrest

    Participants received an initial intraarterial infusion (during flow arrest) of 45 mg/m\^2 nanoparticle paclitaxel immediately following revascularization.

    Drug: Nanoparticle Paclitaxel

  • Experimental
    During Flow Arrest + IV

    Participants received an initial intraarterial infusion (during flow arrest) of 45mg/m\^2 nanoparticle paclitaxel immediately following revascularization and a follow-up intravenous injection of 45 mg/m\^2 at 7 days.

    Drug: Nanoparticle Paclitaxel

Interventions

  • Nanoparticle albumin-bound paclitaxel, 45 mg/m\^2.

    Also known as: ABI-007, Abraxane®, Coroxane™

06

What researchers measure

Primary outcomes

  1. Target Vessel Revascularization at 9 Months

    Target vessel revascularization (TVR) was defined as percutaneous revascularization or bypass of the target lesion or any segment of the artery containing the target lesion. The percentage of participants requiring revascularization of the target vessel was determined by stenosis of \> 50% confirmed by angiography.

    Time frame: 9 months

Secondary outcomes

  1. Systolic Velocity Ratio (SVR) > 2.0

    The percentage of participants with a systolic velocity ratio \> 2.0 assessed using lower extremity arterial duplex ultrasound.

    Time frame: 9 months

  2. Change From Baseline in Walking Impairment Questionnaire (WIQ) Score

    The Walking Impairment Questionnaire (WIQ) is utilized to characterize a patient's walking ability. Scores range from 0 (no difficulty) to 100 (much difficulty).

    Time frame: Baseline and Month 9

  3. Decrease in Ankle Brachial Index (ABI) > 0.15

    The percentage of participants with a decrease in the Ankle Brachial Index (ABI) \> 0.15. Ankle Brachial Index = Systolic Ankle Pressure / Systolic Brachial Pressure.

    Time frame: Baseline and Month 9

  4. Target Lesion Revascularization (TLR) at 9 Months

    Target lesion revascularization (TLR) was defined as repeat percutaneous intervention or bypass surgery of the previously treated target lesion (or blockage). The percentage of participants requiring revascularization of the target lesion was determined by stenosis of \> 50% confirmed by angiography.

    Time frame: 9 months

  5. Number of Deaths

    Number of patients who died due to any cause.

    Time frame: Up to 11 months

  6. Number of Participants With Myocardial Infarction (MI)

    The number of patients experiencing Myocardial Infarction (MI) during the study. Myocardial Infarction was defined as new pathologic Q waves of at least 0.04 seconds, or an increase in serum creatine kinase to more than twice the normal code together with a pathologic increase in myocardial isoenzymes.

    Time frame: Up to 11 months

  7. Number of Participants With a Stroke

    The number of patients experiencing a stroke during the study. Stroke was defined as any sudden development of neurological deficits lasting more than 24 hours, and if a brain imaging study is performed it shows an infarction or hemorrhage. A transient ischemic attack is a neurological deficit lasting less than 24 hours and, if an imaging study is performed, shows no evidence of infarction or hemorrhage.

    Time frame: Up to 11 months

  8. Minimum Lumen Diameter

    Minimum lumen diameter (MLD) is defined as the smallest diameter in millimeters (mm) in the arterial segment of interest measured angiographically.

    Time frame: 9 months

  9. Late Loss

    Late loss is defined as minimum lumen diameter (MLD) immediately post-procedure minus MLD at the time of follow-up, in mm.

    Time frame: Day 1 (following revascularization) and 9 months

  10. Percentage of Participants With Binary Restenosis

    Binary restenosis was defined by a \>50% diameter stenosis at follow-up study, assessed by angiography.

    Time frame: 9 months

  11. Diameter Stenosis

    Diameter stenosis is calculated as \[1 - (minimum lumen diameter (MLD) / reference vessel diameter)\] \* 100, where the reference vessel diameter is the vessel diameter measured in a healthy segment of the target vessel proximal as close as possible to the lesion.

    Time frame: 9 months

07

Results

Posted Mar 13, 2012

Participant flow

Participant flow — Overall Study
MilestoneControlProximal to Lesion + IVDuring Flow ArrestDuring Flow Arrest + IV
Started0312
Completed0000
Not completed0312
Withdrew: Adverse event0100
Withdrew: Study termination0212

Outcome measures

PrimaryTarget Vessel Revascularization at 9 Months

Target vessel revascularization (TVR) was defined as percutaneous revascularization or bypass of the target lesion or any segment of the artery containing the target lesion. The percentage of participants requiring revascularization of the target vessel was determined by stenosis of \> 50% confirmed by angiography.

Time frame:
9 months
Reported as:
Number · percentage of participants

No measurements were reported for this outcome.

SecondarySystolic Velocity Ratio (SVR) > 2.0

The percentage of participants with a systolic velocity ratio \> 2.0 assessed using lower extremity arterial duplex ultrasound.

Time frame:
9 months
Reported as:
Number · percentage of participants

No measurements were reported for this outcome.

SecondaryChange From Baseline in Walking Impairment Questionnaire (WIQ) Score

The Walking Impairment Questionnaire (WIQ) is utilized to characterize a patient's walking ability. Scores range from 0 (no difficulty) to 100 (much difficulty).

Time frame:
Baseline and Month 9
Reported as:
Mean · scores on a scale

No measurements were reported for this outcome.

SecondaryDecrease in Ankle Brachial Index (ABI) > 0.15

The percentage of participants with a decrease in the Ankle Brachial Index (ABI) \> 0.15. Ankle Brachial Index = Systolic Ankle Pressure / Systolic Brachial Pressure.

Time frame:
Baseline and Month 9
Reported as:
Number · percentage of participants

No measurements were reported for this outcome.

SecondaryTarget Lesion Revascularization (TLR) at 9 Months

Target lesion revascularization (TLR) was defined as repeat percutaneous intervention or bypass surgery of the previously treated target lesion (or blockage). The percentage of participants requiring revascularization of the target lesion was determined by stenosis of \> 50% confirmed by angiography.

Time frame:
9 months
Reported as:
Number · percentage of participants

No measurements were reported for this outcome.

SecondaryNumber of Deaths

Number of patients who died due to any cause.

Time frame:
Up to 11 months
Reported as:
Number · participants
Number of Deaths
participantsControlProximal to Lesion + IVDuring Flow ArrestDuring Flow Arrest + IV
Number of Deaths—100
SecondaryNumber of Participants With Myocardial Infarction (MI)

The number of patients experiencing Myocardial Infarction (MI) during the study. Myocardial Infarction was defined as new pathologic Q waves of at least 0.04 seconds, or an increase in serum creatine kinase to more than twice the normal code together with a pathologic increase in myocardial isoenzymes.

Time frame:
Up to 11 months
Reported as:
Number · participants
Number of Participants With Myocardial Infarction (MI)
participantsControlProximal to Lesion + IVDuring Flow ArrestDuring Flow Arrest + IV
Number of Participants With Myocardial Infarction (MI)—000
SecondaryNumber of Participants With a Stroke

The number of patients experiencing a stroke during the study. Stroke was defined as any sudden development of neurological deficits lasting more than 24 hours, and if a brain imaging study is performed it shows an infarction or hemorrhage. A transient ischemic attack is a neurological deficit lasting less than 24 hours and, if an imaging study is performed, shows no evidence of infarction or hemorrhage.

Time frame:
Up to 11 months
Reported as:
Number · participants
Number of Participants With a Stroke
participantsControlProximal to Lesion + IVDuring Flow ArrestDuring Flow Arrest + IV
Number of Participants With a Stroke—000
SecondaryMinimum Lumen Diameter

Minimum lumen diameter (MLD) is defined as the smallest diameter in millimeters (mm) in the arterial segment of interest measured angiographically.

Time frame:
9 months
Reported as:
Mean · mm

No measurements were reported for this outcome.

SecondaryLate Loss

Late loss is defined as minimum lumen diameter (MLD) immediately post-procedure minus MLD at the time of follow-up, in mm.

Time frame:
Day 1 (following revascularization) and 9 months
Reported as:
Mean · mm

No measurements were reported for this outcome.

SecondaryPercentage of Participants With Binary Restenosis

Binary restenosis was defined by a \>50% diameter stenosis at follow-up study, assessed by angiography.

Time frame:
9 months
Reported as:
Number · percentage of participants

No measurements were reported for this outcome.

SecondaryDiameter Stenosis

Diameter stenosis is calculated as \[1 - (minimum lumen diameter (MLD) / reference vessel diameter)\] \* 100, where the reference vessel diameter is the vessel diameter measured in a healthy segment of the target vessel proximal as close as possible to the lesion.

Time frame:
9 months
Reported as:
Mean · percent diameter stenosis

No measurements were reported for this outcome.

Adverse events

Collected over Up to 11 months. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Control———
Proximal to Lesion + IV—1/3 (33.3%)1/3 (33.3%)
During Flow Arrest—0/1 (0%)0/1 (0%)
During Flow Arrest + IV—0/2 (0%)0/2 (0%)
Most frequent serious events
Most frequent serious events
EventControlProximal to Lesion + IVDuring Flow ArrestDuring Flow Arrest + IV
Cardiac arrestCardiac disorders—1/30/10/2
Most frequent other events
Most frequent other events
EventControlProximal to Lesion + IVDuring Flow ArrestDuring Flow Arrest + IV
DiarrhoeaGastrointestinal disorders—1/30/10/2
Pain in extremityGastrointestinal disorders—1/30/10/2
DisorientationPsychiatric disorders—1/30/10/2
HaematomaVascular disorders—1/30/10/2

Baseline characteristics

Age Continuous
Age Continuous(years)ControlProximal to Lesion + IVDuring Flow ArrestDuring Flow Arrest + IVTotal
Mean—69.7 ± 10.5084.0 ± NA69.0 ± 12.7371.8 ± 10.59
Gender
Gender(participants)ControlProximal to Lesion + IVDuring Flow ArrestDuring Flow Arrest + IVTotal
Female—0011
Male—3115
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)ControlProximal to Lesion + IVDuring Flow ArrestDuring Flow Arrest + IVTotal
Asian—0011
White, Non-Hispanic and Non-Latino—3115
08

Study locations

7 sites
  • UC Davis Medical Center, Ellison Ambulatory Care Center Cardiology Suite 3400
    Sacramento, California 95817, United States
  • Vascular & Interventional Physicians
    Gainsville, Florida 32605, United States
  • Midwest Cardiovascular Research Foundation
    Davenport, Iowa 52803, United States
  • Michigan Vascular Research Center
    Flint, Michigan 48507, United States
  • Holy Name Hospital
    Teaneck, New Jersey 07666, United States
  • Lindner Clinical Trials Center
    Cincinnati, Ohio 45219, United States
  • Rhode Island Hospital
    Providence, Rhode Island 02903, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2008, a primary completion of Aug 2009 and a completion of Sep 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2012, 2 years 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 16, 2007
First posted
Aug 20, 2007
Start
Jan 2008
Primary completionActual
Aug 2009
CompletionActual
Sep 2009
Results first posted
Mar 13, 2012
Last update
Mar 13, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 13, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00518284
Responsible party
Sponsor
First posted
Aug 20, 2007
Start date
Jan 2008
Primary completion
Aug 2009
Completion
Sep 2009
Results posted
Mar 13, 2012
Last update
Mar 13, 2012

Study contacts

José Iglesias, MD
study director · Celgene Corporation

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Feb 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Albumin-Bound Paclitaxel

Start the discussion